Eagle Wealth Advisors’s AbbVie ABBV Stock Holding History

Eagle Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$331K	Buy	1,315 +152	+13%	+$32.7K	0.25%	74
2026 Q1	$253K	Buy	1,163 +12	+1%	+$2.66K	0.23%	83
2025 Q4	$263K	Buy	+1,151	New	+$262K	0.22%	76

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eagle Wealth Advisors's ABBV Position: Q2 2026 in Review

Eagle Wealth Advisors increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $32.7K and bringing the position to 1,315 shares worth $331K. The position accounts for 0.25% of the portfolio, ranked #74.

Eagle Wealth Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Eagle Wealth Advisors held 1,315 shares of AbbVie worth $331K as of Q2 2026.
Eagle Wealth Advisors bought 152 AbbVie shares in Q2 2026, an estimated $32.7K.
AbbVie made up 0.25% of Eagle Wealth Advisors's portfolio in Q2 2026, its #74 holding.
Eagle Wealth Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eagle Wealth Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.